Recent advances in our understanding of peptide hormone receptors and RAMPS

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 5, 1999, Pages 440-448

  Sexton, Patrick M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Calcitonin; CGRP; Family B; G protein coupled receptor; Peptide hormone; Receptor activity modifying protein

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CALCITONIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PARATHYROID HORMONE; PEPTIDE HORMONE; RECEPTOR BLOCKING AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE;

BINDING SITE; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR OCCUPANCY; REVIEW;

EID: 0032694232     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bergwitz C, Gardella TJ, Rannery MR, Potts JT Jr, Kronenberg HM, Goldring SR, Juppner H: Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand-receptor interaction. J Biol Chem (1996) 271 (43):26469-26472.
2. Qi LJ, Leung AT, Xiong Y, Marx KA, Abou-Samra AB: Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry (1997) 36:12442-12448.
3. Knudsen SM, Tarns JW, Wulff BS, Fahrenkrug J: A disulfide bond between conserved cysteines in the extracellular loops of the human VIP receptor is required for binding and activation. FEBSLett (1997) 412(1):141-143.
4. Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF: Binding domain of human parathyroid hormone receptor: From conformation to function. Biochemistry (1998) 37:12737-12743.
5. Gelling RW, Wheeler MB, Xue J, Gyomorey S, Nian C, Pederson RA, Mclntosh CH: Localization of the domains involved in ligand binding and activation of the glucosedependent insulinotropic polypeptide receptor. Endocrinology (1997) 138(6):2640-2643.
6. Sydow S, Flaccus A, Fischer A, Spiess J: The role of the fourth extracellular domain of the rat corticotropinreleasing factor receptor type 1 in ligand binding. Eur J Biochem (1999) 259(1 -2):55-62. '
7. Perrin MH, Sutton S, Bain DL, Berggren WT, Vale WW: The first extracellular domain of corticotropin releasing factorR1 contains major binding determinants for urocortin and astressin. Endocrinology (1998) 139:566-570.
8. Olde B, Sabirsh A, Owman C: Molecular mapping of epitopes Involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secret!n receptor. J Mol Neurosci (1998) 11:127-134.
9. Holtmann MH, Hadac EM, Miller LJ: Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive Intestinal polypeptide receptors. Studies of chimeric receptors. J Biol Chem (1995) 270(24):14394-14398.
10. Stroop SD, Nakamuta H, Kuestner RE, Moore Eë, Epand RM: Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions. Endocrinology (1996) 137(11):4752-4756.
11. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, Laburthe M: Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Bio! Chem (1996) 271 (22):12795-12800.
12. Lee C, Luck MD, Juppner H, Potts JT Jr, Kronenberg HM, Gardella TJ: Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor reveals PTH-{1-34) binding determinants in the third extracellular loop. Mol Endocrinol (1995) 9(10):1269-1278.
13. Luck MD, Carter PH, Gardella TJ: The (1-14) fragment of parathyroid hormone (PTH) activates intact and aminoterminally truncated PTH-1 receptors. Mol Endocrinol (1999) 13(5):670-680.
14. Hashimoto H, Ogawa N, Hagihara N, Yamamoto K, Imanishi K, Nogi H, Nishino A, Fujita T, Matsuda T, Nagata S, Baba A: Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol Pharmacol (1997) 52(1):128-135.
15. Gourlet P, Vilardaga JP, De Neef P, Waelbroeck M, Vandermeers A, Robberecht P: The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides (1996) 17(5):825-829. • Provides evidence that the far C-terminal residues of secretin and VIP peptides interact predominantly with the N-terminal domain of their receptors.
16. Nicole P, Du K, Couvineau A, Laburthe M: Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: Evidence for difference in the structure-function relationship. J Pharmacol Exp Ther (1998)284(2):744-750.
17. Zhou AT, Bessalle R, Bisello A, Nakamoto C, Rosenblatt M, Suva LJ, Chorev M: Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. Proc Natl Acad Sei USA (1997) 94(8):3644-3649.
18. Bisello A, Adams AE, Mierke DF,' Pellegrini M, Rosenblatt M, Suva LJ, Chorev M: Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies. J Bio! Chem (1998) 273(35):22498-22505. • Identifies an amino acid in transmembrane domain 6 that is in close proximity to PTH residue 1. Provides an important constraint for future modeling of ligand-receptor interactions.
19. Mannstadt M, Luck MD, Gardella TJ, Jüppner H: Evidence for a ligand interaction site at the amino-termlnus of the parathyroid hormone (PTHVPTH-related protein receptor from cross-linking and mutational studies. J Biol Chem (1998) 273(27):16890-16896. • Identifies receptor residues within the far N-terminus (10 and 17), that interact directly with PTH residue 23. Provides an important constraint for future modeling of ligand-receptor interactions.
20. Adams AE, Bisello A, Chorev M, Rosenblatt M, Suva U: Arginine 186 in the extracellular N-termlnal region of the human parathyroid hormone 1 receptor is essential for contact with position 13 of the hormone. Mol Endocrinol (1998)12(11):1673-1683. • Identifies a residue near the junction of the N-temninus and transmembrane domain 1 that is in close proximity to PTH ammo acid 13. Provides an important constraint for future modeling of ligand-receptor interactions.
21. Dong M, Wang Y, Pinon DI, Hadac EM, Miller U: Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the aminoterminal tail of the secretin receptor using photoaffinity labeling. J Blot Chem (1999) 274(2):903-909. • Identifies the far N-terminus (within 1 to 30) of the secretin receptor as being in close proximity to secretin amino acid 22. Provides an important constraint for future modeling of ligandreceptor interactions. Also provides further confirmation (along with PTH1 receptor data) that family B peptides interact with their receptors in a similar manner.
22. Dong M, Wang Y, Hadac EM, Pinon Dl, Holicky E, Miller LJ: Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem (1999)274:19161-19167. • Identifies a far N-terminal, secretin receptor residue (4) that is in close proximity to secretin amino acid 6. Provides an important constraint for future modeling of ligand-receptor interactions.
23. Bisello A, Greenberg Z, Behar V, Rosenblatt M, Suva U, Chorev M: Direct mapping of interactions between PTH and the PTH/PTHrP receptor by photoaffinity cross-linking: Identification of two distinct contact domains. J Bone Miner Res (1997) 12(Supp 1):S363.
24. Pellegrini M, Royo M, Rosenblatt M, Chorev M, Mierke DF: Addressing the tertiary structure of human parathyroid hormone-(1-34). JB/o/Chem (1998) 273(17):10420-10427.
25. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, Hacker C, Hagmann WK, MacCoss M, Chicchi GG, Vicario PP: Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem (1999) 274(13):8694-8697. • Identifies residues in transmembrane domains 2 and 3 of the glucagon receptor important for binding of the small molecule antagonist, but not peptide ligands.
26. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA: Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol (1997) 11(13):2048-2053.
27. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitoninreceptor-like receptor. Nature (1998) 393:333-339.
28. Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gom A, Kolakowski LF Jr, Lodish HF, Goldring SR: Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science (1991) 254:1022-1024. • Along with the secretin and PTH receptors, one of the first described family B GPCRs.
29. Foord SM, Marshall FH: RAMPs: Accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sc/(1999) 20:184-187.
30. Fraser NJ, Wise A, Brown J, McLatchie LM, Main M, Foord SM: The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol (1999) 55(6): 1054-1059. • First chimeric RAMP analysis identifying the N-terminal domain as the major discriminator between phenotype for CGRP and adrenomedullin receptors.
31. Christopouios G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM: Multiple amylin receptors arise from receptor activity modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol (1999) 56:235-242. •• Demonstrates that RAMPs interact with receptors other than CRLR, and that more than one amylin receptor phenotype can be generated via RAMPs 1 and 3, both for endogenously expressed and co-transfected calcitonin receptors. Also the first demonstration of differing effect of RAMPs 2 and 3, and that calcitonin receptors traffic RAMP to the cell surface.
32. Muff R, Leuthäuser K, Bühlmann N, Foord SM, Fischer JA, Bom W: Receptor activity modifying proteins regulate the activity of a calcitonin gene-related peptide receptor in rabbit aortic endothelial cells. F£SS Left (1998) 441(3):366-368. Demonstrates induction of a CGRP receptor from endogenously expressed CRLR following transfection with RAMP1.
33. Bühlmann N, Leuthäuser K, Muff R, Rscher JA, Born W: A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology (1999) 140(6):2883-2890. • Demonstrates induction of an adrenomedullin receptor following transfection alone of CRLR into cells endogenously expressing high levels of RAMP2.
34. Chen WJ, Armour S, Way J, Chen G, Watson C, living P, Cobb J, Kadwell S, Beaumont K, Rimele T, Kenakin T: Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors. Mol Pharmacol (1997) 52(6):1164-1175.
35. Perry KJ, Quiza M, Myers DE, Morfis M, Christopouios G, Sexton PM: Characterization of amylin and calcitonin receptor binding in the mouse alpha-thyroid-stimulating hormone thyrotroph cell line. Endocrinology (1997) 138(8):3486-3496. • Identifies glycosylation differences between endogenously expressed amylin and calcitonin receptors.
36. Ho HH, Gilbert MT, Nussenzveig DR, Gershengorn MC: Glycosylation is important for binding to human calcitonin receptors. Biochemistry (1999) 38(6):1866-1872! • Reveals that glycosylation on the two membrane proximal sites for N-linked glycosylation are critical for high affinity calcitonin binding. Has potential implications for mechanism of RAMP modification of phenotype.
37. Muff R, Buhlmann N, Fischer JA, Born W: An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology (1999) 140(6):2924-2927. • Demonstrates that RAMPs can also interact with calcitonin receptors to generate novel amylin receptors.
38. Moore EE, Kuestner RE, Stroop SD, Grant FJ, Matthewes SL, Brady CL, Sexton PM, Findlay DM: Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol Endocrine/ (1995)9(8):959-968.
39. Turner PR, Bambino T, Nissenson RA: A putative selectivity filter in the G-protein-coupled receptors for parathyroid hormone and secretion. J Biol Chem (1996) 271(16):92059208. • Demonstrates that peptide selectivity of receptors can be altered by a single point mutation in transmembrane domain 2. This may have relevance for RAMP interaction.
40. Baker EK, Colley NJ, Zuker CS: The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex in vivo with its protein target rhodopsin. EMBO J (1994) 13(20):4886-4895.
41. Dwyer ND, Troemel ER, Sengupta P, Bargmann CI: Odorant receptor localization to olfactory cilia is mediated by ODR4, a novel membrane-associated protein. Cell (1998) 93(3):455-466.
42. Chen C, Dagnino R Jr, De Souza EB, Grigoriadis DE, Huang CQ, Kirn Kl, Liu Z, Moran T, Webb TR, Whitten JP, Xie YF, McCarthy JR: Design and synthesis of a series of nonpeptide high-affinity human corticotropin-releasing factorl receptor antagonists. J Med Chem (1996) 39(22):4358-4360. • Reports one of the first, high affinity, non-peptide antagonists fora family B GPCR.
43. Hodge CN, Aldrich PE, Wasserman ZR, Femandez CH, Nemeth GA, Arvanitis A, Cheeseman RS, Chorvat RJ, Ciganek E, Christos TE, Gilligan PJ, Krenitsky P, Scholfield E, Strucely P: Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies. J Wed Chem (1999) 42(5):819-832.